COSTA MESA, Calif., March 20 /PRNewswire-FirstCall/ -- Oxygen Biotherapeutics, Inc. (OTC Bulletin Board: OXBO) today announced the expansion of the company's board of directors with the addition of J. Melville Engle to the board.
Engle has over 27 years experience in leading both large and small companies. He has raised money on Wall Street, launched hundreds of products, and has a broad management and financial background, including six years at Dey LP, where he was the firm's president and CEO. Dey LP, a Napa, CA-based specialty pharmaceutical company, is focused on the development and commercialization of products for respiratory, allergy and other breathing disorders. Engle's background also includes senior executive positions with Merck Generics Group, a division of Merck KGaA, and Allergan, Inc.
"I'm very pleased that Mel has agreed to join our board," said Chris J. Stern, company chairman and CEO. "He has the business acumen and experience in the pharmaceutical industry to help us develop and grow as we work to bring Oxycyte(R)-based products to the market. During his tenure at Dey, sales increased from $250 million to over $600 million. Our board and company will be stronger with his involvement."
"I'm excited about the promise of Oxycyte and what I can see as the potential for this company. I'm looking forward to working with Chris and the other board members to help bring that potential to reality," said Engle.
About Oxygen Biotherapeutics, Inc.
Oxygen Biotherapeutics, Inc. is dedicated to commercializing innovative pharmaceuticals and medical devices in the field of oxygen therapeutics and continuous substrate monitoring. The company has under development a perfluorocarbon therapeutic oxygen carrier and liquid ventilation product (Oxycyte(R)) and an implantable glucose sensor. These products are based upon core technologies that include biomedical applications for PFCs and medical and industrial applications for biosensors. Each of the product candidates is designed with advantages over currently marketed products in major markets including traumatic brain injury, sickle cell crisis pain, trauma, wound care, acute respiratory distress syndrome, stroke, myocardial infarction, surgery, and diabetes. More information is available at www.oxybiomed.com.
|SOURCE Oxygen Biotherapeutics, Inc.|
Copyright©2009 PR Newswire.
All rights reserved